Sarepta Therapeutics (SRPT) Given “Outperform” Rating at Leerink Swann

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “outperform” rating restated by research analysts at Leerink Swann in a report released on Friday, January 19th, The Fly reports. They currently have a $77.00 target price on the biotechnology company’s stock. Leerink Swann’s target price indicates a potential upside of 31.49% from the company’s current price. Leerink Swann also issued estimates for Sarepta Therapeutics’ FY2020 earnings at $2.91 EPS.

Several other research analysts also recently commented on the company. BidaskClub upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. HC Wainwright restated a “buy” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, January 9th. Zacks Investment Research downgraded Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 5th. Janney Montgomery Scott initiated coverage on Sarepta Therapeutics in a research report on Wednesday, January 3rd. They set a “buy” rating and a $75.00 price target for the company. Finally, Oppenheimer reiterated a “buy” rating and set a $76.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, December 27th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and seventeen have given a buy rating to the company’s stock. Sarepta Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $64.65.

Sarepta Therapeutics (NASDAQ:SRPT) traded up $3.42 during mid-day trading on Friday, hitting $58.56. The stock had a trading volume of 1,499,510 shares, compared to its average volume of 1,800,000. Sarepta Therapeutics has a 12 month low of $26.26 and a 12 month high of $68.90. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52. The company has a market cap of $3,780.00, a P/E ratio of -28.71 and a beta of 1.49.

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $55.89, for a total value of $372,618.63. Following the transaction, the director now directly owns 13,333 shares of the company’s stock, valued at approximately $745,181.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 9.60% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Alliancebernstein L.P. boosted its position in shares of Sarepta Therapeutics by 63.3% during the second quarter. Alliancebernstein L.P. now owns 118,310 shares of the biotechnology company’s stock valued at $3,988,000 after purchasing an additional 45,860 shares in the last quarter. 361 Capital LLC bought a new stake in shares of Sarepta Therapeutics during the third quarter valued at approximately $1,914,000. Janney Montgomery Scott LLC bought a new stake in shares of Sarepta Therapeutics during the third quarter valued at approximately $474,000. Hikari Power Ltd bought a new stake in shares of Sarepta Therapeutics during the third quarter valued at approximately $1,134,000. Finally, Oppenheimer & Co. Inc. boosted its position in shares of Sarepta Therapeutics by 53.0% during the third quarter. Oppenheimer & Co. Inc. now owns 33,592 shares of the biotechnology company’s stock valued at $1,524,000 after purchasing an additional 11,639 shares in the last quarter. Institutional investors own 82.41% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/12/sarepta-therapeutics-srpt-stock-rating-reaffirmed-by-leerink-swann.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

The Fly

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply